Core Viewpoint - The company has established and improved its governance structures, including the shareholders' meeting, board of directors, supervisory board, independent directors, and board secretary system, in preparation for its initial public offering on the Growth Enterprise Market [1][2][4][5][6]. Shareholders' Meeting System - The company has adopted its Articles of Association and rules for the shareholders' meeting, establishing a standardized system that allows shareholders to exercise their rights in accordance with the Company Law and the Articles of Association [1]. - The shareholders' meeting has convened 11 times during the reporting period, adhering to legal and regulatory requirements to protect the rights of the company and its shareholders [1]. Board of Directors System - The board of directors, consisting of 9 members, is responsible for managing the company's operations and is accountable to the shareholders' meeting [2][3]. - The board has held meetings in compliance with the Articles of Association and has effectively participated in decision-making regarding profit distribution, listing plans, and the appointment of senior management [3]. Supervisory Board System - The supervisory board, composed of 3 members, serves as the company's oversight body, ensuring the protection of the rights of the company, shareholders, and employees [4]. - The supervisory board has convened 16 meetings during the reporting period, fulfilling its responsibilities in accordance with legal and regulatory requirements [4]. Independent Directors System - The company has appointed 3 independent directors, ensuring that they constitute at least one-third of the board, and has established guidelines for their roles and responsibilities [5]. - Independent directors actively participate in decision-making and have contributed to the protection of minority shareholders' rights and the overall governance structure [5]. Board Secretary System - The board secretary is responsible for information disclosure, investor relations, and organizing board and shareholders' meetings, ensuring compliance with relevant regulations [6]. - Since the appointment of the board secretary, the company has maintained effective communication with shareholders and has contributed to the improvement of the governance structure [6].

上海建发致新医疗科技集团股份有限公司（以下简称"公司"）申请首次公 开发行股票并在创业板上市，根据《首次公开发行股票注册管理办法》《公开发 行证券的公司信息披露内容与格式准则第 58 号——首次公开发行股票并上市申 请文件》等有关规定，现将审计委员会及其他专门委员会的设置情况说明如下： 一、专门委员会的建立健全情况 公司董事会下设战略、提名、薪酬与考核、审计四个专门委员会。专门委员 会成员全部由董事组成，其中薪酬与考核委员会、提名委员会、审计委员会中独 立董事占多数并担任召集人，审计委员会中担任召集人的独立董事是会计专业人 士。 上海建发致新医疗科技集团股份有限公司 关于审计委员会及其他专门委员会的设置情况说明 深圳证券交易所： 《董事会提名委员会工作细则》 《董事会薪酬与考核委员会工作细则》 《董 事会审计委员会工作细则》的议案，对战略委员会、提名委员会、薪酬与考核委 员会、审计委员会的人员组成、职责权限、评审及工作程序、议事规则等作出了 规定。自董事会各专门委员会设立至今，各委员能切实履行职责，保障了公司的 规范运行。 （以下无正文，为《上海建发致新医疗科技集团股份有限公司关于审计委员会及 其他专门委员会 ...

Group 1: Investor Relations Management - The company has established a comprehensive information disclosure system to ensure transparency and protect investors' rights, including the development of various management regulations such as the "Independent Director Work Guidelines" and "Investor Relations Management System" [1][2] - The company has set up a dedicated office for investor relations, led by the board secretary, to facilitate communication with investors and provide necessary information [1][2] - Future plans include enhancing communication with investors, particularly public investors, and establishing a stable and harmonious relationship through the implementation of the "Investor Relations Management System" [2][3] Group 2: Dividend Distribution Policy - The company aims to implement a stable and sustainable profit distribution policy, prioritizing cash dividends while considering long-term growth and operational sustainability [3][4] - Cash dividends will be prioritized, with a minimum of 30% of the average distributable profits over three years to be distributed if conditions are met [4][5] - The board will consider various factors, including industry characteristics and major investment plans, when proposing differentiated cash dividend policies [4][5] Group 3: Shareholder Voting Mechanism - The company has adopted a cumulative voting system for the election of directors and supervisors, allowing shareholders to concentrate their voting rights [9][10] - All proposals at the shareholder meeting will be voted on individually, ensuring transparency and accountability in decision-making [9][10] - The company will provide online voting options to facilitate participation from shareholders, particularly small and medium-sized investors [11]

Core Viewpoint - Shanghai Jianfa Zhixin Medical Technology Group Co., Ltd. has received approval for its initial public offering (IPO) of ordinary shares (A shares) and listing on the ChiNext board, with the application approved by the Shenzhen Stock Exchange and registered by the China Securities Regulatory Commission [1][19]. Group 1: IPO Details - The company plans to issue 63,193,277 new shares, representing approximately 15.00% of the total share capital post-IPO [19]. - The IPO will be conducted through a combination of strategic placements, offline inquiries to qualified investors, and online offerings to public investors holding non-restricted A shares or depository receipts [19]. - The offering price will be determined based on the median and weighted average of bids from offline investors, excluding the highest bids [3][19]. Group 2: Subscription Process - Offline subscription will occur from 9:30 AM to 3:00 PM, while online subscription will be from 9:15 AM to 11:30 AM and 1:00 PM to 3:00 PM on September 16, 2025 [2]. - Investors do not need to pay subscription funds at the time of bidding [2]. - The strategic placement will involve senior management and core employees, as well as large enterprises with strategic cooperation relationships [3][19]. Group 3: Investor Requirements - Qualified offline investors must submit pricing basis and proposed prices or price ranges before participating in the inquiry [4][8]. - The minimum proposed subscription quantity for offline investors is set at 2.5 million shares, with increments of 1 million shares thereafter [5][6]. - Investors must ensure that their proposed subscription amounts do not exceed their total assets as of the last month-end prior to the inquiry [6][10]. Group 4: Issuance and Allocation - The final allocation of shares will be based on effective subscription multiples, industry valuation levels, and the company's fundamentals [11][12]. - The offline issuance will adopt a proportionate lock-up method, with 90% of shares being freely tradable upon listing and 10% subject to a 6-month lock-up period [13][19]. - The underwriting will be conducted on a balance underwriting basis by the lead underwriter, CITIC Securities [19][20].

（原标题：科创板今日大宗交易成交3.82亿元） 13只科创板股大宗交易平台今日发生交易，合计成交3.82亿元。 证券时报•数据宝统计显示，9月3日共有13只科创板股发生大宗交易，合计成交42笔，累计成交量548.27万股，成交额合计3.82亿元。 统计显示，成交金额最多的是惠泰医疗，今日大宗交易成交量为65.55万股，成交金额1.63亿元；其次是爱博医疗、威腾电气，今日大宗交易金额 分别为7019.24万元、4950.00万元。 折溢价情况来看，今日出现大宗交易的科创板股中，均为折价成交，大宗交易成交价格相对收盘价折价率居前的有惠泰医疗、燕麦科技、东微半 导等，折价率分别为21.31%、18.24%、15.00%。 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 相关ETF 科创100ETF华夏 (产品代码: 588800) 股价表现方面，今日科创50指数下跌1.64%，科创板股中，今日上涨的有146只，占24.91%，今日发生大宗交易的科创板股平均上涨2.66%，其 中，涨幅居前的为东微半导、益方生物、炬光科技等，涨幅分别为12.28%、5.36%、4.36%，跌幅居前的有燕麦科技、磁谷科技、 ...

Group 1 - The company, Weining Health, stated on September 3 that it will explore various medical AI application scenarios based on market demand and its own advantages, rather than being limited to a specific application scenario [2]

Core Viewpoint - Furu Pharmaceutical Co., Ltd. has seen a stock price increase of 5.38% to 66.38 CNY per share, with a total market capitalization of 17.589 billion CNY as of September 3 [1] Company Overview - Furu Pharmaceutical, established on December 26, 2001, and listed on January 20, 2010, is located in Chaoyang District, Beijing. The company specializes in the production and sales of drugs in the liver disease sector, as well as instrument research and sales, and medical services [1] - The revenue composition of Furu Pharmaceutical is as follows: 67.57% from equipment and technology, 27.47% from pharmaceuticals, 4.30% from medical services, and 0.65% from other sources [1] Shareholder Information - Southern Fund's Southern Medical Health Flexible Allocation Mixed A Fund (000452) is among the top ten circulating shareholders of Furu Pharmaceutical, having increased its holdings by 159,000 shares in the second quarter, totaling 3.8899 million shares, which represents 1.66% of the circulating shares [2] - The fund has achieved a year-to-date return of 55.82%, ranking 462 out of 8,180 in its category, and a one-year return of 55.38%, ranking 2,082 out of 7,967 [2] Fund Manager Performance - The fund manager of Southern Medical Health Flexible Allocation Mixed A Fund is Wang Zhengjiao, who has been in the position for 7 years and 41 days. The fund's total asset size is 2.417 billion CNY, with the best return during Wang's tenure being 74.43% and the worst being -53.83% [3] Fund Holdings - Southern Medical Health Flexible Allocation Mixed A Fund has Furu Pharmaceutical as its sixth-largest holding, with 5.22% of the fund's net value allocated to this stock [4]

Core Viewpoint - The stock market activity has significantly increased since the beginning of the year, particularly in the Asia-Pacific region, marking a return of positive market sentiment after three years [1][3]. Group 1: Market Sentiment and Activity - Overall market sentiment has undergone a notable transformation since the beginning of the year, with expectations for active stock capital markets, merger and acquisition (M&A) markets, and bond capital markets from now until next year [3]. - The current market momentum is primarily driven by the technology sector, with industrial technology and medical technology identified as key focus areas, alongside signs of recovery in the financial services sector [3]. Group 2: Japan Market Insights - The Japanese market is currently experiencing heightened activity, with corporate reforms translating into increased M&A activity, and financial investment institutions actively seizing opportunities [3]. - There is a growing optimism regarding the Japanese market as reforms continue, despite the economy showing moderate growth, indicating clear signs of a turning point that has significantly improved market sentiment [3]. - A comprehensive recovery in transaction activities across major industries is anticipated from the second half of 2025 to 2026 [3].

Core Insights - The article highlights the importance of inclusive finance in supporting the growth of technology startups, particularly those that are asset-light and high-risk, which often struggle to secure traditional financing [1][2] - The case study of Tianjin's Small and Medium Enterprise Credit Financing Guarantee Co., Ltd. (Tianjin SME Guarantee) illustrates how innovative financing solutions can effectively address the funding challenges faced by tech startups [1][2] Group 1: Financing Solutions - Tianjin SME Guarantee's entrepreneurial guarantee business provides government-backed loans to support individual entrepreneurship and small businesses, aiming to alleviate financing difficulties [2][3] - The organization has developed a "bank supermarket" model, aggregating resources from over twenty banks to negotiate lower financing costs for startups [8][10] - The collaborative due diligence and parallel approval process with banks significantly reduces loan approval times, enhancing efficiency for startups [9][10] Group 2: Case Studies of Supported Companies - Lingzhi Haoyue Aviation Technology Co., Ltd. received 4 million yuan in credit support, resulting in a comprehensive loan rate of less than 2%, which is significantly lower than market rates [3][8] - Tianjin Tianrong Environmental Technology Co., Ltd. benefited from a 10 million yuan guarantee loan, with a minimal guarantee fee of 40,000 yuan, allowing for sustained investment in technology and market expansion [4][5][8] - Zhongke Xinchuan Medical Technology (Tianjin) Co., Ltd. secured 1 million yuan in funding to support its product launch, demonstrating the critical role of Tianjin SME Guarantee in facilitating market entry for new companies [5][11] Group 3: Innovative Risk Management - Tianjin SME Guarantee employs a "technology points system" to evaluate startups, reducing reliance on traditional financial metrics and enabling more companies to access financing [10][11] - The organization has implemented a "party-building credit enhancement" model, linking the effectiveness of a company's party-building work to its credit assessment, which has proven to enhance repayment reliability [10][11] Group 4: Comprehensive Support Services - Tianjin SME Guarantee offers services that extend beyond loan provision, supporting companies throughout their lifecycle from startup to growth and maturity phases [11][12] - The organization provides additional resources such as industry information and policy interpretation, positioning itself as a partner in the growth of tech companies [12][13] - As of July 2025, Tianjin SME Guarantee has provided 390 million yuan in entrepreneurial guarantee loans to 212 startups, demonstrating its significant impact on local economic development [12][13]

Core Viewpoint - The article emphasizes the significant advancement of Foundation Models (FM) in the potential applications of artificial intelligence (AI) in clinical care, highlighting the need for rigorous prospective validation and randomized controlled trials to bridge the gap between AI capabilities and real-world clinical environments [2][3][6]. Group 1: Foundation Model Development - A multi-modal visual-language ophthalmic foundation model named EyeFM was developed, which was validated through a prospective deployment across various global regions, including Asia, North America, Europe, and Africa [3][6]. - EyeFM was pre-trained using a diverse dataset of 14.5 million eye images, enabling it to perform various core clinical tasks effectively [6][11]. Group 2: Clinical Evaluation and Effectiveness - The effectiveness of EyeFM as a clinical assistance tool was evaluated through a randomized controlled trial involving 668 participants, showing a higher correct diagnosis rate of 92.2% compared to 75.4% in the control group [11][13]. - The study also indicated improved referral rates (92.2% vs 80.5%) and better self-management adherence (70.1% vs 49.1%) among the intervention group using EyeFM [11][13]. Group 3: Application and Future Implications - EyeFM serves as a comprehensive assistance system for ophthalmology, with potential applications across various clinical scenarios, enhancing the diagnostic capabilities of ophthalmologists and improving patient outcomes [12][13].